TOPICAL PRODRUGS FOR TREATMENT OF ACNE AND SKIN DISEASES

Award Information
Agency:
Department of Health and Human Services
Amount:
$263,000.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1987
Phase:
Phase II
Agency Tracking Number:
2956
Solicitation Topic Code:
N/A
Small Business Information
Molecular Design International
P.o. Box 41777, Memphis, TN, 38174
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Harlie A. Parish
 Principal Investigator
 (901) 454-1919
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE LONG-TERM OBJECTIVE OF THIS PROJECT IS TO DEVELOP A COMMERCIAL PRODUCT FOR THE TOPICAL TREATMENT OF ACNE AND SKIN DISEASES. THE SPECIFIC AIM OF THE PROPOSAL IS TO INVENT A PRODRUG THAT CAN BE USED EFFECTIVELY AND SAFELY FOR THE TOPICAL TREATMENT OF ACNE. SINCE ISOTRETINOIN (13-CIS-RETINOIC ACID, ACCUTANE-ROCHE) ADMINISTERED ORALLY CAUSES BIRTH DEFECTS AND APPLIED TOPICALLY IS IRRITATING, WE HAVE DESIGNED PRODRUGS OF ISOTRETINOIN. THESE PRODRUGS ARE INTENDED 1.TO BE APPLIED TOPICALLY, 2.TO MAKE ISOTRETINOIN BIOAVAILABLE AT THE TARGET SITE BY HYDROLYSIS OF THE PRODRUG IN THE SKIN, AND THREE PRODRUGS HAVE ALREADY BEEN SYNTHESIZED AND TESTED IN THE TOPICAL RHINO MOUSE ASSAY AND THE ORAL HAMSTER SEBACEOUS GLAND ASSAY. ONE OF OUR COMPOUNDS, MDI 3831101, IS AS EFFECTIVE AS ISOTRETINOIN IN THE SAME ASSAYS. SINCE THIS IS A NEW COMPOUND, A PATENT APPLICATION HAS BEEN FILED.WE PROPOSE TO SYNTHESIZE ADDITIONAL SAMPLES OF MDI 3831101 AND ADDITIONAL PRODRUGS OF ISOTRETINOIN IN ORDER TO OPTIMIZE OUR LEAD COMPOUND.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government